Immunophenotyping of Inclusion Body Myositis Blood T and NK Cells

Overview

Journal Neurology

Specialty Neurology

Date 2022 Feb 8

PMID 35131904

Authors

Namita A Goyal

Gerald Coulis

Jorge Duarte

Philip K Farahat

Ali H Mannaa

Jonathan Cauchii

Tyler Irani

Nadia Araujo

Leo Wang

Marie Wencel

Vivian Li

Lishi Zhang

Steven A Greenberg

Tahseen Mozaffar

S Armando Villalta

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: To evaluate the therapeutic potential of targeting highly differentiated T cells in patients with inclusion body myositis (IBM) by establishing high-resolution mapping of killer cell lectin-like receptor subfamily G member 1 (KLRG1) within the T and natural killer (NK) cell compartments.

Methods: Blood was collected from 51 patients with IBM and 19 healthy age-matched donors. Peripheral blood mononuclear cells were interrogated by flow cytometry using a 12-marker antibody panel. The panel allowed the delineation of naive T cells (Tn), central memory T cells (Tcm), 4 stages of effector memory differentiation T cells (Tem 1-4), and effector memory re-expressing CD45RA T cells (TemRA), as well as total and subpopulations of NK cells based on the differential expression of CD16 and C56.

Results: We found that a population of KLRG1 Tem and TemRA were expanded in both the CD4 and CD8 T-cell subpopulations in patients with IBM. KLRG1 expression in CD8 T cells increased with T-cell differentiation with the lowest levels of expression in Tn and highest in highly differentiated TemRA and CD56CD8 T cells. The frequency of KLRG1 total NK cells and subpopulations did not differ between patients with IBM and healthy donors. IBM disease duration correlated with increased CD8 T-cell differentiation.

Discussion: Our findings reveal that the selective expansion of blood KLRG1 T cells in patients with IBM is confined to the TemRA and Tem cellular compartments.

Citing Articles

Inclusion body myositis and immunosenescence: current evidence and future perspectives.

Allameen N, Salam S, Reddy V, Machado P Rheumatology (Oxford). 2024; 64(3):952-961.

PMID: 39504446 PMC: 11879327. DOI: 10.1093/rheumatology/keae614.

Sporadic inclusion body myositis-derived myotube culture revealed muscle cell-autonomous expression profiles.

Suzuki N, Kanzaki M, Koide M, Izumi R, Fujita R, Takahashi T PLoS One. 2024; 19(8):e0306021.

PMID: 39088432 PMC: 11293708. DOI: 10.1371/journal.pone.0306021.

The role of KLRG1: a novel biomarker and new therapeutic target.

Zhang Y, Chen S, Tang X, Peng Y, Jiang T, Zhang X Cell Commun Signal. 2024; 22(1):337.

PMID: 38898461 PMC: 11186184. DOI: 10.1186/s12964-024-01714-7.

Inclusion body myositis, viral infections, and TDP-43: a narrative review.

Vacaras V, Vulturar R, Chis A, Damian L Clin Exp Med. 2024; 24(1):91.

PMID: 38693436 PMC: 11062973. DOI: 10.1007/s10238-024-01353-9.

Identification of distinct immune signatures in inclusion body myositis by peripheral blood immunophenotyping using machine learning models.

McLeish E, Sooda A, Slater N, Beer K, Cooper I, Mastaglia F Clin Transl Immunology. 2024; 13(4):e1504.

PMID: 38585335 PMC: 10990804. DOI: 10.1002/cti2.1504.

References

Pandya J, Fasth A, Zong M, Arnardottir S, Dani L, Lindroos E . Expanded T cell receptor Vβ-restricted T cells from patients with sporadic inclusion body myositis are proinflammatory and cytotoxic CD28null T cells. Arthritis Rheum. 2010; 62(11):3457-66. DOI: 10.1002/art.27665. View

Schmidt J, Dalakas M . Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives. Expert Rev Clin Immunol. 2013; 9(11):1125-33. DOI: 10.1586/1744666X.2013.842467. View

Kelly-Rogers J, Madrigal-Estebas L, OConnor T, Doherty D . Activation-induced expression of CD56 by T cells is associated with a reprogramming of cytolytic activity and cytokine secretion profile in vitro. Hum Immunol. 2006; 67(11):863-73. DOI: 10.1016/j.humimm.2006.08.292. View

Mastaglia F, Needham M . Inclusion body myositis: a review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches. J Clin Neurosci. 2014; 22(1):6-13. DOI: 10.1016/j.jocn.2014.09.012. View

Van Acker H, Capsomidis A, Smits E, Van Tendeloo V . CD56 in the Immune System: More Than a Marker for Cytotoxicity?. Front Immunol. 2017; 8:892. PMC: 5522883. DOI: 10.3389/fimmu.2017.00892. View

Li Y, Li B, You Z, Zhang J, Wei Y, Li Y . Cytotoxic KLRG1 expressing lymphocytes invade portal tracts in primary biliary cholangitis. J Autoimmun. 2019; 103:102293. DOI: 10.1016/j.jaut.2019.06.004. View

Needham M, Mastaglia F . Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment. Clin Neurophysiol. 2016; 127(3):1764-73. DOI: 10.1016/j.clinph.2015.12.011. View

Gupta S, Su H, Bi R, Agrawal S, Gollapudi S . Life and death of lymphocytes: a role in immunesenescence. Immun Ageing. 2005; 2:12. PMC: 1236953. DOI: 10.1186/1742-4933-2-12. View

Williams T, Chataway J . Immune-mediated encephalitis with daclizumab: The final nail. Mult Scler. 2018; 25(5):753-754. DOI: 10.1177/1352458518791374. View

10.

Duftner C, Dejaco C, Hengster P, Bijuklic K, Joannidis M, Margreiter R . Apoptotic effects of antilymphocyte globulins on human pro-inflammatory CD4+CD28- T-cells. PLoS One. 2012; 7(3):e33939. PMC: 3316508. DOI: 10.1371/journal.pone.0033939. View

11.

Spaulding C, Guo W, Effros R . Resistance to apoptosis in human CD8+ T cells that reach replicative senescence after multiple rounds of antigen-specific proliferation. Exp Gerontol. 1999; 34(5):633-44. DOI: 10.1016/s0531-5565(99)00033-9. View

12.

Pearl J, Parris J, Hale D, Hoffmann S, Bernstein W, McCoy K . Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant. 2005; 5(3):465-74. DOI: 10.1111/j.1600-6143.2005.00759.x. View

13.

Lindberg C, Trysberg E, Tarkowski A, Oldfors A . Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology. 2003; 61(2):260-2. DOI: 10.1212/01.wnl.0000071852.27182.c7. View

14.

Strioga M, Pasukoniene V, Characiejus D . CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease. Immunology. 2011; 134(1):17-32. PMC: 3173691. DOI: 10.1111/j.1365-2567.2011.03470.x. View

15.

Posnett D, Edinger J, Manavalan J, Irwin C, Marodon G . Differentiation of human CD8 T cells: implications for in vivo persistence of CD8+ CD28- cytotoxic effector clones. Int Immunol. 1999; 11(2):229-41. DOI: 10.1093/intimm/11.2.229. View

16.

Vallejo A, Schirmer M, Weyand C, Goronzy J . Clonality and longevity of CD4+CD28null T cells are associated with defects in apoptotic pathways. J Immunol. 2000; 165(11):6301-7. DOI: 10.4049/jimmunol.165.11.6301. View

17.

Greenberg S, Pinkus J, Amato A, Kristensen T, Dorfman D . Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. Brain. 2016; 139(Pt 5):1348-60. DOI: 10.1093/brain/aww024. View

18.

Hohlfeld R, Engel A, Goebels N, Behrens L . Cellular immune mechanisms in inflammatory myopathies. Curr Opin Rheumatol. 1998; 9(6):520-6. DOI: 10.1097/00002281-199711000-00007. View

19.

Salajegheh M, Rakocevic G, Raju R, Shatunov A, Goldfarb L, Dalakas M . T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis. Neurology. 2007; 69(17):1672-9. DOI: 10.1212/01.wnl.0000265398.77681.09. View

20.

Dimachkie M, Barohn R . Inclusion body myositis. Neurol Clin. 2014; 32(3):629-46, vii. PMC: 4115580. DOI: 10.1016/j.ncl.2014.04.001. View